Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Oncology Clinical Research GLP-1 Drugs Market Trends Obesity Treatment Regulatory Approval Regulatory Affairs Market Competition

Eli Lilly Tops GLP‑1 Market as Sales Soar

Strong first-quarter growth from tirzepatide and Mounjaro pushed the company’s valuation higher, with dividend yield remaining about 0.6%.

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Researchers Find 14‑Protein Blood Signature That Predicts Lung Cancer Years Ahead

Supreme Court Clears Path for Generic 'Skinny Labels' in Unanimous Hikma Ruling

Flu Drug Class Prevents Glycan Loss Linked to Cognitive Decline in People With HIV

Fulcrum Halts Pociredir Development After FDA Flags PRC2 Cancer Risk

Eli Lilly Rides Breakthrough Retatrutide Data and $4 Billion Vaccine Push to Record Highs

New Hepatitis B Drug Produces Functional Cure in About One in Five Patients

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

Canada Expands Access to Semaglutide With Home Delivery and First G7 Generics

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Milestone Posts Q1 Loss as CARDAMYST Launch Shows Early Uptake and AFib-RVR Phase 3 Begins

PolyPid Nears Completion of Rolling FDA Filing for D‑PLEX100

Lilly Launches First Amyloid-Targeting Alzheimer’s Drug in India at Rs 91,688 a Dose

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

UNAM Scientists Turn Scorpion Venom and Habanero Chili Into Experimental Antibiotics